• 1
    Nanda K, McCrory DC, Myers ER, Bastian LA, Hasselblad V, Hickey JD, Matchar DB. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 2000; 132: 8109.
  • 2
    Fahey MT, Irwig L, Macaskill P. Meta-analysis of Pap test accuracy. Am J Epidemiol 1995; 141: 6809.
  • 3
    Abu-Jawdeh GM, Trawinski G, Wang HH. Histocytological study of squamous atypia on Pap smears. Mod Pathol 1994; 7: 9204.
  • 4
    Howell LP, Davis RL. Follow-up of Papanicolaou smears diagnosed as atypical squamous cells of undetermined significance. Diagn Cytopathol 1996; 14: 204.
  • 5
    Auger M, Charbonneau M, Arseneau J. Atypical squamous cells of undetermined significance. A cytohistologic study of 52 cases. Acta Cytol 1997; 41: 16715.
  • 6
    Ghoussoub RA, Rimm DL. Degree of dysplasia following diagnosis of atypical squamous cells of undetermined significance is influenced by patient history and type of follow-up. Diagn Cytopathol 1997; 17: 149.
  • 7
    Williams ML, Rimm DL, Pedigo MA, Frable WJ. Atypical squamous cells of undetermined significance: correlative histologic and follow-up studies from an academic medical center. Diagn Cytopathol 1997; 16: 17.
  • 8
    Yang M, Zachariah S. ASCUS on cervical cytologic smears. Clinical significance. J Reprod Med 1997; 42: 32931.
  • 9
    Nyirjesy I, Billingsley FS, Forman MR. Evaluation of atypical and low-grade cervical cytology in private practice. Obstet Gynecol 1998; 92: 6017.
  • 10
    Eltabbakh GH, Lipman JN, Mount SL, Morgan A. Significance of atypical squamous cells of undetermined significance on ThinPrep Papanicolaou smears. Gynecol Oncol 2000; 79: 449.
  • 11
    Morin C, Bairati I, Bouchard C, Fortier M, Roy M, Moore L, Meisels A. Cytologic predictors of cervical intraepithelial neoplasia in women with an ASCUS Pap smear. Acta Cytol 2000; 44: 57686.
  • 12
    Nygard JF, Sauer T, Skjeldestad FE, Skare GB, Thoresen SO. CIN 2/3 and cervical cancer after an ASCUS pap smear. A 7-year, prospective study of the Norwegian population-based, coordinated screening program. Acta Cytol 2003; 47: 9911000.
  • 13
    Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 129.
  • 14
    Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 51827.
  • 15
    Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003; 88: 6373.
  • 16
    Clifford GM, Smith JS, Aguado T, Franceschi S. 2003. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 2003; 89: 1015.
  • 17
    Munger K, Phelps WC, Bubb V, Howley PM, Schlegel R. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol 1989; 63: 441721.
  • 18
    Hudson JB, Bedell MA, McCance DJ, Laiminis LA. Immortalization and altered differentiation of human keratinocytes in vitro by the E6 and E7 open reading frames of human papillomavirus type 18. J Virol 1990; 64: 51926.
  • 19
    zur Hausen H, de Villiers EM. Human papillomaviruses. Annu Rev Microbiol 1994; 48: 42747.
  • 20
    Sotlar K, Selinka HC, Menton M, Kandolf R, Bultmann B. Detection of human papillomavirus type 16 E6/E7 oncogene transcripts in dysplastic and nondysplastic cervical scrapes by nested RT-PCR. Gynecol Oncol 1998; 69: 11421.
  • 21
    Mandelblatt JS, Lawrence WF, Womack SM, Jacobson D, Yi B, Hwang YT, Gold K, Barter J, Shah K. 2002. Benefits and costs of using HPV testing to screen for cervical cancer. JAMA 2002; 287: 237281.
  • 22
    Lytwyn A, Sellors JW, Mahony JB, Daya D, Chapman W, Howard M, Roth P, Lorincz AT, Gafni A, Walter SD. Adjunctive human papillomavirus testing in the 2-year follow-up of women with low-grade cervical cytologic abnormalities: a randomized trial and economic evaluation. Arch Pathol Lab Med 2003; 127: 116975.
  • 23
    Nygard JF, Skare GB, Thoresen SO. The cervical cancer screening programme in Norway, 1992-2000: changes in Pap smear coverage and incidence of cervical cancer. J Med Screen 2002; 9: 8691.
  • 24
    Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997; 102: 38.
  • 25
    Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338: 4238.
  • 26
    Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, Rozendaal L, Remmink AJ, Risse EK, van der Linden HC, Voorhorst FJ, Kenemans P, Meijer CJ. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 1999; 354: 205.
  • 27
    Woodman CB, Collins S, Winter H, Bailey A, Ellis J, Prior P, Yates M, Rollason TP, Young LS. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 2001; 357: 18316.
  • 28
    Cuschieri KS, Whitley MJ, Cubie HA. Human papillomavirus type specific DNA and RNA persistence—implications for cervical disease progression and monitoring. J Med Virol 2004; 73: 6570.
  • 29
    Schiffman M, Solomon D. Findings to date from the ASCUS-LSIL Triage Study (ALTS). Arch Pathol Lab Med 2003; 127: 9469.
  • 30
    Manos MM, Kinney WK, Hurley LB, Sherman ME, Shieh-Ngai J, Kurman RJ, Ransley JE, Fetterman BJ, Hartinger JS, McIntosh KM, Pawlick GF, Hiatt RA. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA 1999; 281: 160510.
  • 31
    Solomon D, Schiffman M, Tarone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst 2001; 93: 2939.
  • 32
    Cox JT, Schiffman M, Solomon D. Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy. Am J Obstet Gynecol 2003; 188: 140612.
  • 33
    Ostor AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 1993; 12: 18692.
  • 34
    Melnikow J, Nuovo J, Willan AR, Chan BK, Howell LP. Natural history of cervical squamous intraepithelial lesions: a meta-analysis: Obstet Gynecol 1998; 92: 72735.
  • 35
    Molden T, Kraus I, Karlsen F, Skomedal H, Nygård JF, Hagmar B. Comparison of human papillomavirus mRNA and DNA detection: a cross-sectional study of 4136 women older than 30 years of age with a two year follow-up of HSIL. Cancer Epidemiol Biomarkers Prev 2004; in press.